BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31005045)

  • 1. Oxytocin in the tumor microenvironment is associated with lower inflammation and longer survival in advanced epithelial ovarian cancer patients.
    Cuneo MG; Szeto A; Schrepf A; Kinner EM; Schachner BI; Ahmed R; Thaker PH; Goodheart M; Bender D; Cole SW; McCabe PM; Sood AK; Lutgendorf SK; Mendez AJ
    Psychoneuroendocrinology; 2019 Aug; 106():244-251. PubMed ID: 31005045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
    Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
    BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
    Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
    BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant ascites enhances migratory and invasive properties of ovarian cancer cells with membrane bound IL-6R in vitro.
    Kim S; Gwak H; Kim HS; Kim B; Dhanasekaran DN; Song YS
    Oncotarget; 2016 Dec; 7(50):83148-83159. PubMed ID: 27825119
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokine profiling of ascites at primary surgery identifies an interaction of tumor necrosis factor-α and interleukin-6 in predicting reduced progression-free survival in epithelial ovarian cancer.
    Kolomeyevskaya N; Eng KH; Khan AN; Grzankowski KS; Singel KL; Moysich K; Segal BH
    Gynecol Oncol; 2015 Aug; 138(2):352-7. PubMed ID: 26001328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diurnal cortisol and survival in epithelial ovarian cancer.
    Schrepf A; Thaker PH; Goodheart MJ; Bender D; Slavich GM; Dahmoush L; Penedo F; DeGeest K; Mendez L; Lubaroff DM; Cole SW; Sood AK; Lutgendorf SK
    Psychoneuroendocrinology; 2015 Mar; 53():256-67. PubMed ID: 25647344
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation and characterization of stromal progenitor cells from ascites of patients with epithelial ovarian adenocarcinoma.
    Ho CM; Chang SF; Hsiao CC; Chien TY; Shih DT
    J Biomed Sci; 2012 Feb; 19(1):23. PubMed ID: 22330345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Normalization of the ovarian cancer microenvironment by SPARC.
    Said N; Socha MJ; Olearczyk JJ; Elmarakby AA; Imig JD; Motamed K
    Mol Cancer Res; 2007 Oct; 5(10):1015-30. PubMed ID: 17951402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overexpression of the recently identified oncogene REDD1 correlates with tumor progression and is an independent unfavorable prognostic factor for ovarian carcinoma.
    Chang B; Meng J; Zhu H; Du X; Sun L; Wang L; Li S; Yang G
    Diagn Pathol; 2018 Nov; 13(1):87. PubMed ID: 30428884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Positive Psychosocial Factors and Oxytocin in the Ovarian Tumor Microenvironment.
    Cuneo MG; Szeto A; Schrepf A; Thaker PH; Goodheart M; Cole SW; Sood AK; McCabe PM; Mendez AJ; Lutgendorf SK
    Psychosom Med; 2021 Jun; 83(5):417-422. PubMed ID: 34080583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
    Alberti C; Pinciroli P; Valeri B; Ferri R; Ditto A; Umezawa K; Sensi M; Canevari S; Tomassetti A
    Oncogene; 2012 Sep; 31(37):4139-49. PubMed ID: 22158046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biomarker potential of IL-6 and VEGF-A in ascitic fluid of epithelial ovarian cancer patients.
    Dalal V; Kumar R; Kumar S; Sharma A; Kumar L; Sharma JB; Roy KK; Singh N; Vanamail P
    Clin Chim Acta; 2018 Jul; 482():27-32. PubMed ID: 29572186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of IL-6 and IL-8 ascites levels in ovarian cancer patients.
    Lane D; Matte I; Rancourt C; Piché A
    BMC Cancer; 2011 May; 11():210. PubMed ID: 21619709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-6 level in serum and ascites as a prognostic factor in patients with epithelial ovarian cancer.
    Plante M; Rubin SC; Wong GY; Federici MG; Finstad CL; Gastl GA
    Cancer; 1994 Apr; 73(7):1882-8. PubMed ID: 8137215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
    PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The ascites N-glycome of epithelial ovarian cancer patients.
    Biskup K; Braicu EI; Sehouli J; Tauber R; Blanchard V
    J Proteomics; 2017 Mar; 157():33-39. PubMed ID: 28188862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and ascitic fluid levels of interleukin-1, interleukin-6, and tumor necrosis factor-alpha in patients with ovarian epithelial cancer.
    Moradi MM; Carson LF; Weinberg B; Haney AF; Twiggs LB; Ramakrishnan S
    Cancer; 1993 Oct; 72(8):2433-40. PubMed ID: 8402460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell adhesion molecule profiles, proliferation activity and p53 expression in advanced epithelial ovarian cancer induced malignant ascites-Correlation of tissue microarray and cytology microarray.
    Toth L; Nagy B; Mehes G; Laszlo E; Molnar PP; Poka R; Hernadi Z
    Pathol Res Pract; 2018 Jul; 214(7):978-985. PubMed ID: 29801775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
    Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
    Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks.
    Naldini A; Morena E; Belotti D; Carraro F; Allavena P; Giavazzi R
    Thromb Haemost; 2011 Oct; 106(4):705-11. PubMed ID: 21833453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.